Magnetic resonance metabolic imaging of glioma (Q48716454)

14 February 2018

title

Magnetic resonance metabolic imaging of glioma (English)

1 reference

14 February 2018

Dominique Figarella-Branger

author

series ordinal

2

object named as

Dominique Figarella-Branger

1 reference

14 February 2018

Philippe Metellus

1

1 reference

14 February 2018

language of work or name

English

0 references

publication date

1 January 2012

1 reference

14 February 2018

Science Translational Medicine

published in

1 reference

14 February 2018

volume

4

1 reference

14 February 2018

issue

116

1 reference

14 February 2018

page(s)

116ps1

1 reference

14 February 2018

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Molecular Classification of Low-Grade Diffuse Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

FDG-PET as a prognostic factor in high-grade astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3003591

10.1126/SCITRANSLMED.3003591

21 January 2018

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018